GT Biopharma, Inc. GTBP

GTBP Company Overview

GT Biopharma, Inc. is a clinical-stage biotechnology company focused on the development of immuno-oncology therapies designed to harness the immune system to treat cancer and autoimmune diseases. The company operates primarily within the biotechnology and biopharmaceutical industries, with a strategic emphasis on natural killer (NK) cell engager therapeutics and immune-modulating biologics. Its core research platform centers on trispecific and multi-target biologic technologies intended to activate NK cells against tumor cells while minimizing off-target toxicity associated with some conventional immunotherapies.

The company’s primary value drivers are its investigational immunotherapy candidates and proprietary biologic platforms, including programs targeting hematologic malignancies and solid tumors. GT Biopharma has historically evolved through multiple strategic transitions, including earlier operations in specialty pharmaceuticals before shifting its focus toward immuno-oncology and cell-engagement technologies. Public disclosures and corporate filings indicate that the company has concentrated resources on advancing its NK cell engager pipeline and positioning itself within the broader next-generation cancer immunotherapy market.